Eva Wardelmann

List of Publications by Year
in descending order

162	11,279	47006 47	30922 102
papers	citations	h-index	g-index

168	168	168	12032
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recurrent CTNNB1 mutations in craniofacial osteomas. Modern Pathology, 2022, 35, 489-494.	5.5	4
2	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patientsâ€"results of a Nationwide Observational Study (PROSa). British Journal of Cancer, 2022, 126, 1346-1354.	6.4	6
3	Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis, 2022, 11, 20.	4.9	14
4	SS18-SSX drives CREB activation in synovial sarcoma. Cellular Oncology (Dordrecht), 2022, 45, 399-413.	4.4	2
5	Lowâ€density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 494-503.	2.5	12
6	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. Cancer Discovery, 2021, 11, 108-125.	9.4	47
7	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncology Research and Treatment, 2021, 44, 301-312.	1.2	13
8	Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. Cancers, 2021, 13, 586.	3.7	10
9	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. American Journal of Pathology, 2021, 191, 602-617.	3.8	30
10	Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. European Journal of Cancer, 2021, 150, 143-154.	2.8	9
11	The novel <scp>KIT</scp> exon 11 germline mutation <scp>K558N</scp> is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development. Genes Chromosomes and Cancer, 2021, 60, 827-832.	2.8	2
12	Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer, 2021, 154, 253-268.	2.8	8
13	Intensity-modulated Radiotherapy in Patients With Aggressive Extranodal Non-Hodgkin Lymphoma of the Head and Neck. Anticancer Research, 2021, 41, 5131-5135.	1.1	1
14	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
15	Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13â€"Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. Cancers, 2021, 13, 5880.	3.7	4
16	Testing NTRK testing: Wetâ€lab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	2.8	52
17	Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients. Strahlentherapie Und Onkologie, 2020, 196, 117-125.	2.0	9
18	Focal adhesion kinase confers proâ€migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma. Molecular Oncology, 2020, 14, 248-260.	4.6	12

#	Article	IF	Citations
19	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewingâ€™s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. Clinical Orthopaedics and Related Research, 2020, 478, 290-302.	1.5	45
20	Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study. Clinical Sarcoma Research, 2020, 10, 18.	2.3	10
21	Monitoring Endothelin-A Receptor Expression during the Progression of Atherosclerosis. Biomedicines, 2020, 8, 538.	3.2	1
22	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germanyâ€”Cross-Sectional Results of a Nationwide Observational Study (PROSa). Cancers, 2020, 12, 3590.	3.7	31
23	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. JAMA Oncology, 2020, 6, 1241.	7.1	111
24	First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study. Cancers, 2020, 12, 1488.	3.7	15
25	Germline SDHBâ€inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes and Cancer, 2020, 59, 601-608.	2.8	4
26	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. JAMA Surgery, 2020, 155, e200397.	4.3	29
27	ÎºB-Ras and Ral GTPases regulate acinar to ductal metaplasia during pancreatic adenocarcinoma development and pancreatitis. Nature Communications, 2020, 11, 3409.	12.8	24
28	Impact of Adjuvant Radiation Therapy in Patients With Male Breast Cancer: A Multicenter International Analysis. Advances in Radiation Oncology, 2020, 5, 345-349.	1.2	7
29	Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis â€“ A systematic analysis of 204 cases. Scientific Reports, 2020, 10, 3368.	3.3	29
30	<scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp>NTRK</scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.	2.8	27
31	Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nature Communications, 2019, 10, 3475.	12.8	43
32	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€” TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	4.1	22
33	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€“3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1148-1159.	10.7	288
34	Using Image-guided Intensity-modulated Radiotherapy on Patients With Head and Neck Soft-tissue Sarcoma. In Vivo, 2019, 33, 1293-1300.	1.3	6
35	Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumoursÂparticipating in the EORTC STBSG 62024 adjuvant imatinib study. European Journal of Cancer, 2019, 120, 47-53.	2.8	8
36	High Z nanoparticles and radiotherapy: a critical view â€“ Authors' reply. Lancet Oncology, The, 2019, 20, e558.	10.7	2

#	Article	IF	Citations
37	Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Molecular Medicine, 2019, 11, .	6.9	25
38	HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007071.	4.8	49
39	SS18-SSXâ€“Dependent YAP/TAZ Signaling in Synovial Sarcoma. Clinical Cancer Research, 2019, 25, 3718-3731.	7.0	36
40	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). Annals of Hematology, 2019, 98, 1393-1401.	1.8	10
41	Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma. Molecular Cancer Therapeutics, 2019, 18, 834-844.	4.1	28
42	Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Scientific Reports, 2019, 9, 19704.	3.3	18
43	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving firstâ€line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancerâ€Soft Tissue and Bone Sarcoma Group (EORTCâ€STBSG). International Journal of Cancer, 2018, 142, 2610-2620.	5.1	32
44	Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health, 2018, 18, 235.	2.9	64
45	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. European Journal of Cancer, 2018, 94, 187-198.	2.8	6
46	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. Modern Pathology, 2018, 31, 1246-1256.	5.5	76
47	Programmed cell death ligand 1 (PDâ€L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood and Cancer, 2018, 65, e26719.	1.5	39
48	Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget, 2018, 9, 9867-9874.	1.8	57
49	Evolutionary Distance Predicts Recurrence After Liver Transplantation in Multifocal Hepatocellular Carcinoma. Transplantation, 2018, 102, e424-e430.	1.0	4
50	Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. Oncology Research and Treatment, 2018, 41, 736-743.	1.2	13
51	The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2419-2431.	2.5	11
52	Expression levels of hnRNPï¿½K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent ofï¿½p53 pathway activation in rectal adenocarcinoma. International Journal of Molecular Medicine, 2018, 42, 3269-3277.	4.0	5
53	Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. European Respiratory Journal, 2018, 52, 1701637.	6.7	7
54	⁹⁰Yâ€ibritumomabâ€tiuxetan as a therapeutic alternative for follicular lymphoma (<scp>FL</scp>): A singleâ€center experience. European Journal of Haematology, 2018, 101, 514-521.	2.2	3

#	Article	IF	Citations
55	Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS ONE, 2018, 13, e0200163.	2.5	6
56	Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma. Translational Oncology, 2018, 11, 1271-1282.	3.7	20
57	Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. PLoS ONE, 2018, 13, e0193048.	2.5	17
58	Adjuvant chemotherapyâ€"Radiotherapyâ€"Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases. PLoS ONE, 2018, 13, e0197315.	2.5	4
59	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget, 2018, 9, 6536-6549.	1.8	37
60	Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy. Oncotarget, 2018, 9, 30106-30114.	1.8	20
61	Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible. Blood, 2018, 132, 5176-5176.	1.4	0
62	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€"an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30
63	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta OncolÃ³gica, 2017, 56, 1013-1020.	1.8	29
64	Impact of Preoperative Breast MR Imaging and MR-guided Surgery on Diagnosis and Surgical Outcome of Women with Invasive Breast Cancer with and without DCIS Component. Radiology, 2017, 284, 645-655.	7.3	56
65	FUSâ€“DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clinical Cancer Research, 2017, 23, 6227-6238.	7.0	40
66	Spatial investigation of the elemental distribution in Wilsonâ€™s disease liver after d -penicillamine treatment by LA-ICP-MS. Journal of Trace Elements in Medicine and Biology, 2017, 44, 26-31.	3.0	20
67	Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. JAMA Oncology, 2017, 3, 602.	7.1	141
68	SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. British Journal of Cancer, 2017, 116, 1195-1202.	6.4	13
69	SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nature Medicine, 2017, 23, 250-255.	30.7	121
70	CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer, 2017, 113, 121-127.	2.0	14
71	Evaluation of GenoType MTBDR plus by Use of Extracted DNA from Formalin-Fixed Paraffin-Embedded Specimens. Journal of Clinical Microbiology, 2017, 55, 3300-3302.	3.9	3
72	Characterization of the Genetic Program Linked to the Development of Atrial Fibrillation in CREM-Ibî"C-X Mice. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	19

#	Article	IF	Citations
73	Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K). Cancer Letters, 2017, 385, 160-167.	7.2	18
74	Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. BioMed Research International, 2017, 2017, 1-8.	1.9	13
75	Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS ONE, 2017, 12, e0186280.	2.5	47
76	Potential therapeutic impact of CD13 expression in non-small cell lung cancer. PLoS ONE, 2017, 12, e0177146.	2.5	21
77	Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget, 2017, 8, 4268-4276.	1.8	33
78	Differential nuclear <scp>ATRX</scp> expression in sarcomas. Histopathology, 2016, 68, 738-745.	2.9	19
79	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. Journal of Pathology: Clinical Research, 2016, 2, 59-71.	3.0	9
80	Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. Clinical Cancer Research, 2016, 22, 4356-4365.	7.0	68
81	The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells. Tumor Biology, 2016, 37, 6275-6283.	1.8	10
82	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of CancerÂSoft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. European Journal of Cancer, 2016, 58, 62-72.	2.8	114
83	MDM2andCDK4amplifications are rare events in salivary duct carcinomas. Oncotarget, 2016, 7, 75261-75272.	1.8	12
84	Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Oncotarget, 2016, 7, 82458-82472.	1.8	22
85	NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget, 2016, 7, 6774-6789.	1.8	19
86	<scp>SRC</scp> inhibition represents a potential therapeutic strategy in liposarcoma. International Journal of Cancer, 2015, 137, 2578-2588.	5.1	18
87	Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor. Pediatric Blood and Cancer, 2015, 62, 897-900.	1.5	1
88	Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anti-Cancer Drugs, 2015, 26, 843-851.	1.4	15
89	MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas. PLoS ONE, 2015, 10, e0120079.	2.5	18
90	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE, 2015, 10, e0136023.	2.5	202

#	Article	IF	Citations
91	Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget, 2015, 6, 18224-18237.	1.8	71
92	miRNAâ€221 and miRNAâ€222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Molecular Oncology, 2015, 9, 1421-1433.	4.6	71
93	Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Immunology Research, 2015, 3, 547-556.	3.4	39
94	Antibody-Mediated Delivery of Antiâ€“KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clinical Cancer Research, 2015, 21, 1383-1394.	7.0	95
95	Classification ofKIT/PDGFRAwild-type gastrointestinal stromal tumors: implications for therapy. Expert Review of Anticancer Therapy, 2015, 15, 623-628.	2.4	26
96	Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castlemanâ€™s disease. Annals of Hematology, 2015, 94, 1241-1243.	1.8	7
97	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. Clinical Cancer Research, 2015, 21, 4935-4946.	7.0	68
98	The histone code reader SPIN1 controls RET signaling in liposarcoma. Oncotarget, 2015, 6, 4773-4789.	1.8	52
99	FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Oncotarget, 2015, 6, 20215-20230.	1.8	23
100	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research, 2014, 20, 6105-6116.	7.0	129
101	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120, 2325-2333.	4.1	65
102	Management of early asymptomatic gastrointestinal stromal tumors of the stomach. World Journal of Gastrointestinal Endoscopy, 2014, 6, 266.	1.2	42
103	Î²â€Catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoidâ€type fibromatosis. Histopathology, 2013, 62, 294-304.	2.9	93
104	Follicleâ€stimulating hormone receptor expression in soft tissue sarcomas. Histopathology, 2013, 63, 29-35.	2.9	16
105	Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib. Annals of Surgical Oncology, 2013, 20, 586-592.	1.5	110
106	Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations. American Journal of Surgical Pathology, 2013, 37, 1648-1659.	3.7	39
107	SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells. Cancer Research, 2013, 73, 2518-2528.	0.9	62
108	A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Modern Pathology, 2013, 26, 1004-1012.	5.5	51

#	Article	IF	Citations
109	Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biology, 2013, 14, r137.	9.6	78
110	A Novel Germline KIT Mutation (p.L576P) in a Family Presenting With Juvenile Onset of Multiple Gastrointestinal Stromal Tumors, Skin Hyperpigmentations, and Esophageal Stenosis. American Journal of Surgical Pathology, 2013, 37, 898-905.	3.7	40
111	Loss of the Keratin Cytoskeleton Is Not Sufficient to Induce Epithelial Mesenchymal Transition in a Novel KRAS Driven Sporadic Lung Cancer Mouse Model. PLoS ONE, 2013, 8, e57996.	2.5	27
112	Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. Expert Review of Anticancer Therapy, 2012, 12, 1053-1068.	2.4	9
113	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. JAMA - Journal of the American Medical Association, 2012, 307, 1265.	7.4	832
114	MicroRNA profiling of primary highâ€grade soft tissue sarcomas. Genes Chromosomes and Cancer, 2012, 51, 982-996.	2.8	38
115	Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology, 2012, 61, 59-68.	2.9	82
116	Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open labelÂphase II study in KIT- or PDGFRA-positive tumors.. Journal of Clinical Oncology, 2012, 30, 10031-10031.	1.6	32
117	Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature. Dermatologic Surgery, 2011, 37, 1684-1688.	0.8	8
118	Phosphatidylinositolâ€3â€²â€kinase/AKT signaling is essential in synovial sarcoma. International Journal of Cancer, 2011, 129, 1564-1575.	5.1	47
119	Lineage Conversion of Murine Extraembryonic Trophoblast Stem Cells to Pluripotent Stem Cells. Molecular and Cellular Biology, 2011, 31, 1748-1756.	2.3	37
120	MRI-Guided Breast Biopsy: Influence of Choice of Vacuum Biopsy System on the Mode of Biopsy of MRI-Only Suspicious Breast Lesions. American Journal of Roentgenology, 2010, 194, 1650-1657.	2.2	33
121	Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Research, 2010, 30, 3445-9.	1.1	12
122	Sustained Platelet-Derived Growth Factor Receptor Î± Signaling in Osteoblasts Results in Craniosynostosis by Overactivating the Phospholipase C-Î³ Pathway. Molecular and Cellular Biology, 2009, 29, 881-891.	2.3	41
123	Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. Journal of Cancer Research and Clinical Oncology, 2009, 135, 723-730.	2.5	47
124	Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatric Blood and Cancer, 2009, 53, 1171-1179.	1.5	99
125	Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs. American Journal of Surgical Pathology, 2009, 33, 157-158.	3.7	12
126	Genetic alterations of HLAâ€class II in ovarian cancer. International Journal of Cancer, 2008, 123, 1350-1356.	5.1	18

#	Article	IF	Citations
127	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Modern Pathology, 2008, 21, 476-484.	5.5	165
128	MRI breast screening â€“ Authors' reply. Lancet, The, 2008, 371, 1416.	13.7	1
129	Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1. Clinical Cancer Research, 2008, 14, 4550-4555.	7.0	158
130	Familial Gastrointestinal Stromal Tumors Caused by the Novel KIT Exon 17 Germline Mutation N822Y. American Journal of Surgical Pathology, 2008, 32, 1560-1565.	3.7	28
131	Molekularbiologie und Prognosefaktoren gastrointestinaler mesenchymaler Tumoren. Visceral Medicine, 2007, 23, 113-118.	1.3	2
132	MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet, The, 2007, 370, 485-492.	13.7	658
133	Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer, 2007, 10, 145-152.	5.3	35
134	Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 743-749.	2.8	66
135	Differential diagnosis of gastrointestinal leiomyoma versus gastrointestinal stromal tumor. International Journal of Colorectal Disease, 2006, 21, 84-88.	2.2	14
136	HLA-class II haplotype associations with ovarian cancer. International Journal of Cancer, 2006, 119, 2980-2985.	5.1	29
137	Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. Clinical Cancer Research, 2006, 12, 1743-1749.	7.0	351
138	Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. Journal of Nuclear Medicine, 2006, 47, 616-24.	5.0	119
139	Transcription factor APâ€2Î³, a novel marker of gonocytes and seminomatous germ cell tumors. International Journal of Cancer, 2005, 115, 470-477.	5.1	86
140	Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. International Journal of Cancer, 2005, 115, 591-598.	5.1	31
141	Clear Cell Sarcoma-like Tumor with Osteoclast-like Giant Cells in the Small Bowel: Further Evidence for a New Tumor Entity. International Journal of Surgical Pathology, 2005, 13, 313-318.	0.8	58
142	Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncology, The, 2005, 6, 249-251.	10.7	175
143	Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 8469-8476.	1.6	997
144	Polypoid pleomorphic sarcoma of the colon. Scandinavian Journal of Gastroenterology, 2005, 40, 1502-1506.	1.5	2

#	Article	IF	Citations
145	Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model. Anticancer Research, 2005, 25, 725-9.	1.1	3
146	c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 651-654.	2.8	21
147	Association of Platelet-Derived Growth Factor Receptor Î± Mutations with Gastric Primary Site and Epithelioid or Mixed Cell Morphology in Gastrointestinal Stromal Tumors. Journal of Molecular Diagnostics, 2004, 6, 197-204.	2.8	147
148	Immunohistochemical reactivity of myometrial oxytocin receptor in extracorporeally perfused nonpregnant human uteri. Archives of Gynecology and Obstetrics, 2003, 269, 16-24.	1.7	17
149	Angiogenetic Protooncogene ets-1 Induced Neovascularization Is Involved in the Metastatic Process of Testicular Germ Cell Tumors. European Urology, 2003, 44, 329-336.	1.9	26
150	Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. International Journal of Cancer, 2003, 106, 74-77.	5.1	21
151	Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of thec-kitprotooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. International Journal of Cancer, 2003, 106, 887-895.	5.1	210
152	Current Diagnostic Methods of HER-2/neu Detection in Breast Cancer With Special Regard to Real-Time PCR. American Journal of Surgical Pathology, 2003, 27, 1565-1570.	3.7	33
153	Colorectal carcinoma cells (Caco-2) secrete stroma-inducing growth factors in a stroma-oriented direction. Anticancer Research, 2003, 23, 137-41.	1.1	2
154	Comparative morphometric analysis of primary versus recurrent basal cell carcinoma and of histological subtypes. Significance of morphometry of the nuclei. Anticancer Research, 2003, 23, 2697-700.	1.1	5
155	HLA-G is a potential tumor marker in malignant ascites. Clinical Cancer Research, 2003, 9, 4460-4.	7.0	141
156	c-kit Mutations in Gastrointestinal Stromal Tumors Occur Preferentially in the Spindle Rather Than in the Epithelioid Cell Variant. Modern Pathology, 2002, 15, 125-136.	5.5	112
157	MR Imagingâ€“guided Large-Core (14-Gauge) Needle Biopsy of Small Lesions Visible at Breast MR Imaging Alone. Radiology, 2001, 220, 31-39.	7.3	132
158	Influence of NH₄Cl on Polarized Release of Endogenous Protein Degradation Products and on Morphology in LLC-PK₁ Cells. American Journal of Nephrology, 2000, 20, 74-81.	3.1	6
159	MR Imaging of Pneumonia in Immunocompromised Patients. American Journal of Roentgenology, 2000, 175, 391-397.	2.2	75
160	Breast MR Imaging Screening in 192 Women Proved or Suspected to Be Carriers of a Breast Cancer Susceptibility Gene: Preliminary Results. Radiology, 2000, 215, 267-279.	7.3	541
161	Dynamic Breast MR Imaging: Are Signal Intensity Time Course Data Useful for Differential Diagnosis of Enhancing Lesions?. Radiology, 1999, 211, 101-110.	7.3	1,186
162	The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathologica, 1999, 97, 481-490.	7.7	164